Zacks Research Issues Positive Outlook for BMY Earnings

Bristol Myers Squibb Company (NYSE:BMY) – Research analysts at Zacks Research raised their Q4 2026 EPS estimates for shares of Bristol Myers Squibb in a note issued to investors on Thursday, August 13th. Zacks Research analyst Team now anticipates that the biopharmaceutical company will post earnings per share of $1.64 for the quarter, up from their prior forecast of $1.50. The consensus estimate for Bristol Myers Squibb’s current full-year earnings is $6.96 per share. Zacks Research also issued estimates for Bristol Myers Squibb’s Q1 2027 earnings at $1.40 EPS, Q2 2027 earnings at $1.73 EPS, Q3 2027 earnings at $1.54 EPS, Q4 2027 earnings at $1.52 EPS, FY2027 earnings at $6.20 EPS, Q1 2028 earnings at $1.45 EPS and Q2 2028 earnings at $1.35 EPS.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.60 by $0.44. The firm had revenue of $12.97 billion for the quarter, compared to analyst estimates of $11.74 billion. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The company’s revenue for the quarter was up 5.7% on a year-over-year basis. During the same quarter last year, the firm earned $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS.

Several other analysts also recently issued reports on BMY. Sanford C. Bernstein raised shares of Bristol Myers Squibb from a “market perform” rating to an “outperform” rating in a report on Wednesday, August 5th. Jefferies Financial Group downgraded shares of Bristol Myers Squibb from a “buy” rating to a “hold” rating in a report on Wednesday, August 5th. UBS Group lowered shares of Bristol Myers Squibb from a “buy” rating to a “neutral” rating in a research report on Wednesday, August 5th. Royal Bank Of Canada upped their price target on shares of Bristol Myers Squibb from $60.00 to $64.00 and gave the company a “sector perform” rating in a report on Friday, July 31st. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $59.00 price target (up from $54.00) on shares of Bristol Myers Squibb in a research report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $66.06.

Bristol Myers Squibb Trading Up 1.6%

Shares of BMY stock opened at $64.69 on Friday. Bristol Myers Squibb has a 12 month low of $42.52 and a 12 month high of $68.10. The company has a market cap of $132.15 billion, a PE ratio of 14.25, a price-to-earnings-growth ratio of 0.17 and a beta of 0.22. The company has a quick ratio of 1.38, a current ratio of 1.53 and a debt-to-equity ratio of 1.89. The business’s 50 day moving average is $59.43 and its two-hundred day moving average is $58.93.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Van Hulzen Asset Management LLC acquired a new position in Bristol Myers Squibb in the 2nd quarter valued at approximately $975,000. Peak Asset Management LLC acquired a new position in shares of Bristol Myers Squibb in the 2nd quarter valued at $1,854,000. Fiduciary Financial Advisors acquired a new stake in shares of Bristol Myers Squibb during the 2nd quarter valued at about $158,000. Manning & Napier Advisors LLC bought a new position in Bristol Myers Squibb during the second quarter worth about $10,818,000. Finally, L2 Asset Management LLC bought a new stake in shares of Bristol Myers Squibb in the 2nd quarter valued at approximately $2,597,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol Myers Squibb Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 2nd were paid a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 3.9%. The ex-dividend date was Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio is presently 55.51%.

Trending Headlines about Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: FDA approval strengthens the growth pipeline. The FDA granted accelerated approval to ZENBEXUS, Bristol Myers Squibb’s first CELMoD therapy, in combination with Darzalex Faspro and dexamethasone for certain multiple myeloma patients as early as first relapse. The approval expands the company’s blood-cancer portfolio and could support future revenue growth. US FDA approves Bristol Myers blood cancer treatment
• Positive Sentiment: Zacks Research raised most forward EPS forecasts. The firm increased estimates for fourth-quarter 2026 EPS to $1.64 from $1.50 and FY2027 EPS to $6.20 from $5.93. It also lifted estimates for the first and second quarters of 2027 and the first and second quarters of 2028, suggesting improved expectations for Bristol Myers Squibb’s earnings trajectory. Bristol Myers Squibb analyst estimates
• Neutral Sentiment: Pipeline investment continues. Bristol Myers Squibb launched a Phase 1 study of golcadomide in a renal indication, while its broader growth portfolio reportedly accounts for 56% of revenue. These initiatives may help offset eventual generic pressure on legacy medicines, but clinical and commercial outcomes remain uncertain. Bristol Myers Squibb expands kidney pipeline
• Negative Sentiment: A $6.7 billion Celgene-related lawsuit was revived. An appeals court ruled that UMB Bank could represent former Celgene shareholders, allowing claims that Bristol Myers Squibb delayed approvals for drugs including Breyanzi to proceed. The case introduces potentially significant financial and legal exposure. Lawsuit against Bristol Myers over delayed cancer drug is revived
• Negative Sentiment: A potential AstraZeneca-Bristol Myers merger remains controversial. Reports of a possible $400 billion transaction previously pressured investor sentiment because of the deal’s scale, execution risks, financing requirements and strategic uncertainty. AstraZeneca-Bristol Myers merger analysis

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.